| Autor: |
Roubi, Mohammed, Dalli, Mohammed, Azizi, Salah-eddine, Mahdi, Youness, Mothana, Ramzi A., Alanzi, Abdullah R., Conte, Raffaele, Gseyra, Nadia |
| Předmět: |
|
| Zdroj: |
Journal of Computational Biophysics & Chemistry; Oct2024, Vol. 23 Issue 8, p1057-1071, 15p |
| Abstrakt: |
The primary aim of this investigation is to shed light on potential targets within the main protease Mpro, spike protein of SARS-CoV-2, and Angiotensine converting enzyme 2 (ACE2) for the exploration of novel inhibitors derived from therapeutic natural compounds originating from Atriplex halimus (AH). Many constituents were discerned within AH extracts through comprehensive gas chromatography/mass spectrometry (GC/MS). Notably, compounds, such as oleocanthal and methyl stearate, exhibited promising attributes across various biological activities, including inhibition of key proteins associated with SARS-CoV-2. Furthermore, absorption, distribution, metabolism, excretion, and toxicity (ADMET) settings were evaluated to explore the potential safety and viability of these compounds for pharmaceutical application, affirming their non-interference with human physiology and thus suggesting their suitability for pharmaceutical use. Catechin, epigallocatechin, and methyl stearate were discovered to be the compounds with the highest affinity to the studied protein showing a great potential to be inhibitors to COVID-19. Consequently, this discovery highlights Atriplex halimus as a promising candidate for utilization in combating the virus. In our study, several compounds from Atriplex halimus showed a significant inhibition activity against SARS-COV-2 Mpro and Spike protein, which promotes Atriplex halimus as a potential agent that can be used in the treatment of COVID-19. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
